Çoklu Sistemde Sürekli Apomorfin İnfüzyonu Atrofi Gerçek Dünya Insights From a French Nationwide Retrospective Cohort.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

BackgroundContinuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA).ObjectiveTo assess the 6-month efficacy and tolerability of CSAI in MSA patients.MethodsFrench multicenter retrospective registry-based analysis of CSAI use in MSA. The primary outcome was the 6-month clinical response using the Clinical Global Impression Improvement (CGI-I) scale. Secondary outcomes included tolerability, indications, infusion parameters, and treatment course.ResultsFifty patients were included; 94% had MSA-P. All had motor fluctuations and 88% showed a clinically meaningful dopaminergic response. CSAI was initiated for motor symptoms (100%) or pain (54%). At 6 months, most patients improved (36% "much," 54% "minimally"), mainly due to reduced motor fluctuations. Only 8% discontinued CSAI. Tolerability was rated good/excellent in 74%; 20% reported somnolence and/or orthostatic hypotension.ConclusionIn selected MSA patients with partial dopaminergic responsiveness and motor fluctuations, CSAI provided short-term clinical benefit with acceptable tolerability.

İlgili konular